.Biogen has actually carried out the last rites to its partnership along with Sage Therapeutics on SAGE-324, scrapping the alliance in the consequences of an
Read moreBiogen bows out Denali Alzheimer’s collab
.Biogen has actually handed back rights to an early Alzheimer’s health condition program to Denali Rehabs, going out of a big hole in the biotech’s
Read moreBiogen, UCB record period 3 lupus succeed after stopping working earlier test
.Biogen and UCB’s bank on improving in to stage 3 on the back of a failed research study wants to have actually repaid, along with
Read moreBiogen CMO Maha Radhakrishnan signs up with Sofinnova– Chutes & Ladders
.Accept to recently’s Chutes & Ladders, our summary of substantial management hirings, firings and retirings all over the business. Please send out the praise– or
Read moreBioMarin halts preclinical genetics treatment for heart disease
.After BioMarin administered a springtime tidy of its own pipe in April, the business has decided that it also needs to have to unload a
Read moreBioMarin goes Camping outdoors, striking RNA manage biotech
.BioMarin is actually including kindling to the R&D fire, hitting a match with CAMP4 Therapies for legal rights to select 2 targets pinpointed by the
Read moreBioMarin builds officer crew along with biotech veterinarians– Chutes & Ladders
.Invite to today’s Chutes & Ladders, our summary of notable management hirings, firings and retirings throughout the business. Please deliver the praise– or the negative–
Read moreBioAge introduces $198M from IPO as obesity biotech joins Nasdaq
.BioAge Labs is introducing virtually $200 thousand via its Nasdaq IPO today, with the earnings earmarked for taking its top obesity drug better right into
Read moreBioAge eyes $180M from IPO, exclusive positioning for being overweight tests
.BioAge Labs is checking out about $180 thousand in preliminary earnings from an IPO as well as an exclusive positioning, funds the metabolic-focused biotech will
Read moreBig pharma, biotech ‘won’t necessarily be actually cooperative’ in artificial intelligence: S&P
.Huge Pharma is putting in greatly in artificial intelligence to slash progression timetables and foster technology. Yet instead of reinforcing future connections with the biotech
Read more